Prediction and prevention of preeclampsy in multiple regnancy after assisted reproductive technologies
DOI:
https://doi.org/10.15574/HW.2022.161.49Keywords:
assisted reproductive technologies, multiple pregnancy, preeclampsia, circulating biomarkers of angiogenesis sFlt-1 and PLGFAbstract
Purpose - to assess the effectiveness of the implemented algorithm of treatment and preventive measures by analyzing the course of pregnancy, childbirth and the condition of newborns in multiple pregnancies after assisted reproductive technologies to assess of changes in biochemical markers of endothelial dysfunction in the detection of pre-clinical manifestations of preeclampsia in pregnant women with multiple pregnancies after the use of assisted reproductive technologies.
Materials and methods. A prospective study of pregnant women with dichorionic diamniotic twins after assisted reproductive technologies was conducted: the Group І (main) - 35 pregnant women with twins who were offered a developed monitoring algorithm; the Group ІІ (control) 27 pregnant women who were monitored according to generally accepted methods of managing multiple pregnancies. Statistical processing of the research results was carried out using standard programs “Microsoft Excel 5.0” and “Statistica 6.0”.
Results. In the Group І 2 cases of moderate preeclampsia were found in 32 and 33 weeks of pregnancy (PLGF results - 63.2 pg/ml and 58.7 pg/ml, sFlt-1/PLGF ratio - 51.7 and 66.3). In the Group II 4 cases of preeclampsia were identified: 2 cases of moderate preeclampsia (PLGF - 74.1 pg/ml and 69.3 pg/ml, sFlt-1/PLGF ratio - 98.6 and 104.5); 2 cases of severe preeclampsia at 33 and 34 weeks (PLGF data - 44.1 pg/ml and 47.3 pg/ml, sFlt-1/ PLGF ratio 122.4 and 130.1) against the background of signs of gestational hypertension. Fetal growth retardation in the Group І was noted in 3 (8.6%) women (І stage - in 2 (5.7%) cases, II stage - in 1 (2.9%) case, III stage was not diagnosed), in the Group II - in 7 (25.9%) women (I stage - in 2 (7.4%) cases, II stage - in 4 (14.8%) cases, III stage - in 1 (3.7%) case). Fetal distress in the Group І was detected in 4 (11.4%) pregnant women (during pregnancy - in 1 (2.9%) case, during deliveries - in 3 (8.6%) cases); in the Group II - in 7 (25.9%) women (during pregnancy - in 5 (18.5%) cases, during deliveries - in 2 (7.4%) cases). Premature deliveries in the Group I was noted in 5 (14.3%) women (before 34 weeks of gestation - in 2 (5.7%) cases, after 34 weeks of gestation - in 3 (8.6%) cases); in the Group II - in 8 (29.6%) women (before 34 weeks of gestation - in 5 (18.5%) cases, after 34 weeks of gestation - in 3 (11.1%) cases). Premature detachment of a normally located placenta was detected in 2 (7.4%) women in the Group II, and in the Group I such cases were not recorded. Vaginal delivery was observed in 14 (40%) women in the Group I and 7 (25.9%) patients in the Group II; cesarean section - in 21 (60%) and 19 (70.4%) women, respectively. Combined delivery was performed in 1 (3.7%) woman of the Group II, and in the Group I - not recorded. Hypoxic-ischemic lesions were detected in 2 (5.7%) children from women of the Group I and in 4 (14.8%) children from mothers of the Group II. Adaptation disorders were noted in 5 (14.3%) cases in the Group I and in 8 (29.6%) cases in the Group II. Transfer to the second stage of treatment required 3 (8.6%) children from mothers of the Group I and 6 (22.2%) children from mothers of the Group II.
Conclusions. The proposed algorithm of modern diagnostic and treatment-prophylactic measures made it possible to reliably reduce the frequency of development of preeclampsia, obstetric and perinatal complications and can be recommended for use in practical health care. The study of the anti-angiogenic factor sFlt-1 and the pro-angiogenic factor PLGF and their ratio is promising in the prediction and early diagnosis of preeclampsia in multiple pregnancies after assisted reproductive technologies. The use of Triage PLGF and sFlt-1/PLGF ratio should be widely implemented in the practice of obstetrician-gynecologists as a prognostic marker for early recognition of preeclampsia in order to reduce perinatal complications, both from the mother and the fetus. Based on monitoring the growth dynamics of the sFlt-1/PLGF ratio, it is possible to predict the early development of preeclampsia even without clinical symptoms, and to make a decision about the possibility of extending the pregnancy or the need for urgent delivery.
The research was carried out in accordance with the principles of the Helsinki Declaration. The study protocol was approved by the Local Ethics Committee of the participating institution. The informed consent of the patient was obtained for conducting the studies.
No conflict of interests was declared by the author.
References
Brustad N et al. (2020). Effect of high-dose vs standard-dose vitamin D supplementation in pregnancy on bone mineralization in offspring until age 6 years: a prespecified secondary analysis of a double-blinded, randomized clinical trial. JAMA pediatrics. 174 (5): 419-427. https://doi.org/10.1001/jamapediatrics.2019.6083; PMid:32091548 PMCid:PMC7042912
Bujold E, Roberge S, Lacasse Y et al. (2010). Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol. 116: 402-414. https://doi.org/10.1097/AOG.0b013e3181e9322a; PMid:20664402
Burton GJ, Redman CW, Roberts JM, Moffett A. (2019). Pre-eclampsia: pathophysiology and clinical implications. BMJ. 366: l2381. https://doi.org/10.1136/bmj.l2381; PMid:31307997
Colafella KMM, Neuman RI, Visser W, Danser AJ, Versmissen J. (2020). Aspirin for the prevention and treatment of pre‐eclampsia: A matter of COX‐1 and/or COX‐2 inhibition? Basic & Clinical Pharmacology & Toxicology. 127 (2): 132-141. https://doi.org/10.1111/bcpt.13308; PMid:31420920 PMCid:PMC7496715
Darmochwal-Kolarz D, Kolarz B, Korzeniewski M, Kimber-Trojnar Z, Patro-Malysza J, Mierzynski R, Oleszczuk J. (2016). A prevention of pre-eclampsia with the use of acetylsalicylic acid and low-molecular weight heparin - molecular mechanisms. Current pharmaceutical biotechnology. 17 (7): 624-628. https://doi.org/10.2174/1389201017666160301103312; PMid:26927215
Hybiak J, Broniarek I, Kiryczyński G, Los LD, Rosik J et al. (2020). Aspirin and its pleiotropic application. European journal of pharmacology. 866: 172762. https://doi.org/10.1016/j.ejphar.2019.172762; PMid:31669590
Ivanchenko SV, Aralova VO. (2019). Issues and problems in diagnosis and treatment of iron-deficiency anemia of pregnant women PHD. Skhidnoievropeiskyi zhurnal vnutrishnoi ta simeinoi medytsyny. 2: 101-104. https://doi.org/10.15407/internalmed2019.02.101
Khanabdali R, Shakouri-Motlagh A, Wilkinson S, Murthi P, Georgiou HM, Brennecke SP, Kalionis B. (2018). Low-dose aspirin treatment enhances the adhesion of preeclamptic decidual mesenchymal stem/stromal cells and reduces their production of pro-inflammatory cytokines. Journal of Molecular Medicine. 96 (11): 1215-1225. https://doi.org/10.1007/s00109-018-1695-9; PMid:30276549
Konijnenberg A, Stokkers EW, van der Post JA et al. (1997). Extensive platelet activation in preeclampsia compared with normal pregnancy: enhanced expression of cell adhesion molecules. Am J Obstet Gynecol. 176 (2): 461-469. https://doi.org/10.1016/S0002-9378(97)70516-7
Larsen S, Bjellanda EK, Haavaldsena C, Eskilda A. (2016). Placental weight in pregnancies with high or low hemoglobin concentrations. European journal of Obstetrics & Gynecology and reproductive biology. 206: 48-52. https://doi.org/10.1016/j.ejogrb.2016.08.039; PMid:27614676
Leaños-Miranda A et al. (2019). Soluble endoglin as a marker for preeclampsia, its severity, and the occurrence of adverse outcomes. Hypertension. 74 (4): 991-997. https://doi.org/10.1161/HYPERTENSIONAHA.119.13348; PMid:31446801
Leow SH, Fisher G, Corker B, Batho O et al. (2020). Future cardio- vascular disease risk for women with gestational hypertension: A Systematic Review and Meta-Analysis. J Am Heart As- soc. 9 (13): e013991. https://doi.org/10.1161/JAHA.119.013991; PMid:32578465 PMCid:PMC7670531
Liu C et al. (2018). Supplementation of folic acid in pregnancy and the risk of preeclampsia and gestational hypertension: a meta-analysis. Archives of gynecology and obstetrics. 298 (4): 697-704. https://doi.org/10.1007/s00404-018-4823-4; PMid:29978414 PMCid:PMC6153594
Loussert L, Vidal F, Parant O, Hamdi SM, Vayssiere C, Guerby P. (2020). Aspirin for prevention of preeclampsia and fetal growth restriction. Prenatal diagnosis. 40 (5): 519-527. https://doi.org/10.1002/pd.5645; PMid:31955436
Luft FC. (2006). Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. Nephrology Dialysis Transplantation. 21 (11): 3052-3054. https://doi.org/10.1093/ndt/gfl439; PMid:16870672
O'Gorman N, Wright D, Rolnik DL, Nicolaides KH, Poon LC. (2016). Study protocol for the randomised controlled trial: combined multimarker screening and randomised patient treatment with ASpirin for evidence-based PREeclampsia prevention (ASPRE). BMJ Open. 6: e011801. https://doi.org/10.1136/bmjopen-2016-011801; PMid:27354081 PMCid:PMC4932292
Poniedziałek-Czajkowska E, Radzisław M. (2021). Could Vitamin D Be Effective in Prevention of Preeclampsia? Nutrients. 13 (11): 3854. https://doi.org/10.3390/nu13113854; PMid:34836111 PMCid:PMC8621759
Purswani JM et al. (2017). The role of vitamin D in pre-eclampsia: a systematic review. BMC pregnancy and childbirth. 17 (1): 1-15. https://doi.org/10.1186/s12884-017-1408-3; PMid:28709403 PMCid:PMC5513133
Queensland Clinical Guidelines. (2021). Hypertension and pregnancy. Queensland Clinical Guidelines: Statewide Maternity and Neonatal Clinical Network (Queensland): 36. URL: https://www.health.qld.gov.au/__data/assets/pdf_file/0034/139948/g-hdp.pdf.
Rehal A et al. (2021). Early vaginal progesterone versus placebo in twin pregnancies for the prevention of spontaneous preterm birth: a randomized, double-blind trial. American Journal of Obstetrics and Gynecology. 224 (1): 86-e1. https://doi.org/10.1016/j.ajog.2020.06.050; PMid:32598909
Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. (2017). The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol. 216: 110-120.e6. https://doi.org/10.1016/j.ajog.2016.09.076; PMid:27640943
Rolnik DL, Nicolaides KH, Poon LC. (2020). Prevention of preeclampsia with aspirin. Am J Obstet Gynecol. 226 (2S): S1108-S1119. https://doi.org/10.1016/j.ajog.2020.08.045; PMid:32835720
Romero R, Conde-Agudelo A, El-Refaie W, Rode L, Brizot ML et al. (2017). Vaginal progesterone decreases preterm birth and neonatal morbidity and mortality in women with a twin gestation and a short cervix: an updated meta-analysis of individual patient data. Ultrasound Obstet Gynecol. 49: 303-314. https://doi.org/10.1002/uog.17397; PMid:28067007 PMCid:PMC5396280
Schröder-Heurich B, Springer CJP, von Versen-Höynck F. (2020). Vitamin D effects on the immune system from periconception through pregnancy. Nutrients. 12 (5): 1432. https://doi.org/10.3390/nu12051432; PMid:32429162 PMCid:PMC7284509
Serban D, Crisan C, Serban C, Serbu IBM, Kundani N et al. (2018). Effects of Acetylsalicylic Acid in Preterm Preeclampsia Prevention. Revista de Chimie (Bucharest). 69: 5. https://doi.org/10.37358/RC.18.5.6289
Serrano NC et al. (2018). Association of pre-eclampsia risk with maternal levels of folate, homocysteine and vitamin B12 in Colombia: A case-control study. PloS one. 13 (12): e0208137. https://doi.org/10.1371/journal.pone.0208137; PMid:30521542 PMCid:PMC6283543
Valdés G. (2022). Focus on today's evidence while keeping an eye on the future: lessons derived from hypertension in women. J Hum Hypertens. https://doi.org/10.1038/s41371-021-00652-y; PMid:35082377
Vdovychenko YP, Gopchuk EN. (2016). Anaemia of pregnant - risk of obstetric and erinatological pathology factor. Health of woman. 3 (109): 62-65.
Vitamin D. Health report. (2016). The Scientific Advisory Committee on Nutrition (SACN) recommendations on vitamin D. Public Health England: 289.
Wagner CL et al. (2017). Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications. Reviews in Endocrine and Metabolic Disorders. 18 (3): 307-322. https://doi.org/10.1007/s11154-017-9414-3; PMid:28214921
Walsh SW, Strauss III JF. (2021). The road to low-dose aspirin therapy for the prevention of preeclampsia began with the placenta. International Journal of Molecular Sciences. 22 (13): 6985. https://doi.org/10.3390/ijms22136985; PMid:34209594 PMCid:PMC8268135
Wei SQ et al. (2012). Longitudinal vitamin D status in pregnancy and the risk of pre‐eclampsia. BJOG: An International Journal of Obstetrics & Gynaecology. 119 (7): 832-839. https://doi.org/10.1111/j.1471-0528.2012.03307.x; PMid:22462640
Wen SW et al. (2018). Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. BMJ. 362. https://doi.org/10.1136/bmj.k3478
Wen, SW et al. (2016). Folic acid supplementation in pregnancy and the risk of pre-eclampsia - a cohort study. PLoS One. 11 (2): e0149818. https://doi.org/10.1371/journal.pone.0149818; PMid:26901463 PMCid:PMC4764298
Wu P, Haththotuwa R, Kwok CS, Babu A, Babu A, Kotronias RA, Rushton C et al. (2017). Preeclampsia and future cardiovascular health: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 10 (2): e003497. https://doi.org/10.1161/CIRCOUTCOMES.116.003497; PMid:28228456
Xu L et al. (2014). The relationship of hypovitaminosis D and IL-6 in preeclampsia. American journal of obstetrics and gynecology. 210 (2): 149-e1. https://doi.org/10.1016/j.ajog.2013.09.037; PMid:24080305 PMCid:PMC4040267
Zheng L et al. (2020). The effect of folic acid throughout pregnancy among pregnant women at high risk of pre-eclampsia: A randomized clinical trial. Pregnancy hypertension. 19: 253-258. https://doi.org/10.1016/j.preghy.2020.01.005 ;PMid:31987769
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ukrainian Journal Health of Woman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
